These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37939825)

  • 21. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
    Butt JH; Kondo T; Jhund PS; Comin-Colet J; de Boer RA; Desai AS; Hernandez AF; Inzucchi SE; Janssens SP; Kosiborod MN; Lam CSP; Langkilde AM; Lindholm D; Martinez F; Petersson M; Shah SJ; Thierer J; Vaduganathan M; Verma S; Wilderäng U; Claggett BC; Solomon SD; McMurray JJV
    J Am Coll Cardiol; 2022 Nov; 80(18):1705-1717. PubMed ID: 36041668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial.
    Poole JE; Bahnson TD; Monahan KH; Johnson G; Rostami H; Silverstein AP; Al-Khalidi HR; Rosenberg Y; Mark DB; Lee KL; Packer DL;
    J Am Coll Cardiol; 2020 Jun; 75(25):3105-3118. PubMed ID: 32586583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan-Meier Curves with Trial Sequential Analysis.
    Soliman Y; Abuelazm M; Amer BE; Hukamdad M; Ellabban MH; Hendi NI; Mouffokes A; AbdelAzeem B; Hassaballa H
    Am J Cardiovasc Drugs; 2024 Sep; 24(5):629-640. PubMed ID: 38963527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.
    Duytschaever M; Demolder A; Phlips T; Sarkozy A; El Haddad M; Taghji P; Knecht S; Tavernier R; Vandekerckhove Y; De Potter T
    Eur Heart J; 2018 Apr; 39(16):1429-1437. PubMed ID: 29211857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
    Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.
    Butt JH; Docherty KF; Jhund PS; de Boer RA; Böhm M; Desai AS; Howlett JG; Inzucchi SE; Kosiborod MN; Martinez FA; Nicolau JC; Petrie MC; Ponikowski P; Bengtsson O; Langkilde AM; Schou M; Sjöstrand M; Solomon SD; Sabatine MS; McMurray JJV; Køber L
    Eur J Heart Fail; 2022 Mar; 24(3):513-525. PubMed ID: 34766424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CURE-AF trial: a prospective, multicenter trial of irrigated radiofrequency ablation for the treatment of persistent atrial fibrillation during concomitant cardiac surgery.
    Damiano RJ; Badhwar V; Acker MA; Veeragandham RS; Kress DC; Robertson JO; Sundt TM
    Heart Rhythm; 2014 Jan; 11(1):39-45. PubMed ID: 24184028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
    Parkash R; Wells GA; Rouleau J; Talajic M; Essebag V; Skanes A; Wilton SB; Verma A; Healey JS; Sterns L; Bennett M; Roux JF; Rivard L; Leong-Sit P; Jensen-Urstad M; Jolly U; Philippon F; Sapp JL; Tang ASL
    Circulation; 2022 Jun; 145(23):1693-1704. PubMed ID: 35313733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and clinical impact of early recurrence of atrial tachyarrhythmia after surgical ablation for atrial fibrillation.
    Choi JH; Hwang KW; Jung SM; Lee SY; Lee SH; Chon MK; Kim JS; Je HG; Park YH; Kim JH; Lee SK; Chun KJ
    J Cardiovasc Electrophysiol; 2020 Nov; 31(11):2898-2906. PubMed ID: 32945008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
    JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Atrial Fibrillation Episode Duration With Arrhythmia Recurrence Following Ablation: A Secondary Analysis of a Randomized Clinical Trial.
    Andrade JG; Deyell MW; Verma A; Macle L; Champagne J; Leong-Sit P; Novak P; Badra-Verdu M; Sapp J; Khairy P; Nattel S
    JAMA Netw Open; 2020 Jul; 3(7):e208748. PubMed ID: 32614422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of repeat catheter ablation vs. antiarrhythmic drug therapy among patients with recurrent atrial tachycardia/atrial fibrillation after atrial fibrillation catheter ablation: data from CHINA-AF registry.
    Zhou L; He L; Wang W; Li C; Li S; Tang R; Sang C; Liu N; Jiang C; Yu R; Long D; Du X; Dong J; Ma C
    Europace; 2023 Feb; 25(2):382-389. PubMed ID: 36156137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Okunrintemi V; Mishriky BM; Powell JR; Cummings DM
    Diabetes Obes Metab; 2021 Jan; 23(1):276-280. PubMed ID: 33001548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
    Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
    Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of atrial fibrillation in patients with enhanced sympathetic tone by pulmonary vein isolation or pulmonary vein isolation and renal artery denervation: clinical background and study design : The ASAF trial: ablation of sympathetic atrial fibrillation.
    de Jong MR; Hoogerwaard AF; Adiyaman A; Smit JJJ; Ramdat Misier AR; Heeg JE; van Hasselt BAAM; Van Gelder IC; Crijns HJGM; Lozano IF; Toquero Ramos JE; Javier Alzueta F; Ibañez B; Rubio JM; Arribas F; Porres Aracama JM; Brugada J; Mont L; Elvan A
    Clin Res Cardiol; 2018 Jul; 107(7):539-547. PubMed ID: 29487995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus.
    Ma N; Wu XY; Ma CS; Liu N; Bai R; Du X; Ruan YF; Dong JZ
    J Huazhong Univ Sci Technolog Med Sci; 2016 Oct; 36(5):646-652. PubMed ID: 27752887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Bansilal S; Bhatt DL; Leiter LA; McGuire DK; Wilding JP; Gause-Nilsson IA; Langkilde AM; Johansson PA; Sabatine MS
    Am Heart J; 2018 Jun; 200():83-89. PubMed ID: 29898853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
    Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
    JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late results of the Cox-maze IV procedure in patients undergoing coronary artery bypass grafting.
    Schill MR; Musharbash FN; Hansalia V; Greenberg JW; Melby SJ; Maniar HS; Sinn LA; Schuessler RB; Moon MR; Damiano RJ
    J Thorac Cardiovasc Surg; 2017 May; 153(5):1087-1094. PubMed ID: 28187972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.